Navigation Links
Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
Date:2/28/2011

high as 50% during that period. Nile believes that the cardiac unloading and renal preserving properties of cenderitide could have a significant benefit to patients during a critical time in their recovery from acute heart failure.

About Heart Failure

Heart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. This hospitalization rate is almost double the rate seen 15 years ago, and is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $33 billion.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting, the anticipated benefits of cenderitide for patients in the post-acute setting, and Nile's plans to initiate clinical trials in the post-acute setting, are forward-looking statements.  Forward-looking statements also include
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
2. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
3. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
4. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
5. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
6. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
7. Echo Therapeutics Announces Appointments to Board of Directors
8. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
9. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
10. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
11. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014 /PRNewswire/ ... announced that its subsidiary, Molecular Profiles Ltd., is set ... the annual CPhI/ICSE Worldwide event in Paris ... with the rapid development of both standard and complex ... platform, which incorporates the company,s existing formulation and analytical ...
(Date:10/1/2014)... 1, 2014  Varian Medical Systems (NYSE: ... for the fourth quarter of fiscal year 2014 following ... 2014.  The news release will be followed by a ... PT.  The news release and a link to the ... website at: www.varian.com/investor .  To access the teleconference ...
(Date:10/1/2014)...  SI-BONE, Inc., a medical device company that pioneered the ... invasive surgical (MIS) device indicated for fusion for certain disorders ... its European operations with the formation of a GmbH and ... Manager, Germany.  Mr. Schaber will join former Kyphon colleague ... , Middle East and Asia ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4
(Date:10/2/2014)... Philadelphia, PA (PRWEB) October 02, 2014 ... winners of the 2014 BIG Awards for Business ... companies and organizations with a proprietary judging process ... from around the globe. , “The winners this ... said Russ Fordyce, Managing Director of the Business ...
(Date:10/2/2014)... Salamon HealthDay Reporter ... with a neurotic personality style and prolonged stress may ... research suggests. Tracking 800 women over nearly four ... anxious, jealous and moody -- which they defined as ... risk of developing Alzheimer,s compared to women scoring lowest ...
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... to a major highway may raise your risk for high ... 5,000 postmenopausal women, those who lived within 109 yards of ... developing high blood pressure than women living at least half ... this study highlight the importance of our physical environment on ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... Columbia now have a total of 500 confirmed cases of ... children since the summer, U.S. health officials reported Wednesday. ... recent weeks, but it,s not clear what role -- if ... Health officials are also trying to determine if the ...
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2
... and British scientists have now found that it is helpful in ... warfare. , ... Manhasset, NY (Vocus) May 6, 2009 ... found that it is helpful in delaying the effects of ricin, ...
... May 6 Parishioners at Guardian Angels Catholic Church in ... shelf -- they actually grow it themselves. The project is ... by the Institute for Agriculture and Trade Policy (IATP) and ... Cross) that demonstrate a growing nationwide movement within the faith ...
... 6 Symmetry Medical Inc. (NYSE: SMA ), ... device industry and other medical markets, announced today that Brian ... Hite, Senior Vice President and Chief Financial Officer, are scheduled ... 2009 Healthcare Conference at the Palace Hotel in New York ...
... Mich., May 6 Perrigo Company (Nasdaq: ... Directors declared a quarterly dividend of $0.055 per share, ... on May 29, 2009. Perrigo Company is a leading ... (OTC) and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ...
... PA, 6 May 2009 Obstructive sleep apnea (OSA) ... in heart failure (HF) patients managed with beta-blockers and ... Journal of Cardiac Failure ( http://www.elsevier.com/locate/cardfail ), ... of Sleep Apnea in Patients with Heart Failure and ...
... lack of guidance and training provided for nurses involved in ... , Writing in the May issue of the Journal ... highlighted the need for an audit of current UK services ... , But they point out that the basic issues they ...
Cached Medicine News:Health News:Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 2Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 3Health News:Report Finds Faith Organizations Building Community, Improving Health Through Healthy Foods 4Health News:Symmetry Medical to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference 2Health News:Sleep apnea may not be closely linked to heart failure severity 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 2Health News:Nurses are assessing mothers with mental health issues despite lack of guidance and formal training 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: